Kinase 2027: 12th SCI-RSC Symposium on Kinase Modulators

Synopsis

With more than 100 clinically approved small molecules, the field of kinase modulation continues to attract significant investment from the drug discovery community and attention from academia. The 12th SCI-RSC symposium on kinase modulator design will encompass plenary lectures on emerging topics and case studies of ongoing programmes as well as successful past programmes. A range of topics including brain penetrant and inhaled kinase inhibitors, kinase chemical probes, allosteric modulators, targeted kinase protein degradation and kinase inhibition for non-oncology indications will be covered, along with views and perspectives on the future directions of kinase modulator research.

---

Attendees

This event is aimed at all scientists interested in furthering their knowledge of kinases and drug design. It will also have wider appeal to members of the drug discovery community eager to understand how enzyme inhibitor programmes are approached and executed across the pharmaceutical industry.

This event will bring together industrial and academic experts representing many of the leading institutions in kinase drug discovery, to discuss a selection of new and emerging topics within the fields of kinase therapeutics for oncology and non-oncology, and foster discussions within the wider industry through networking events such as poster sessions and industrial exhibitions.

---

Call for posters

If you would like to present a poster, please send an abstract of maximum one A4 page or up to 300 words, indicating title and authors, to conferences@soci.org by Friday 12 March 2027 with the subject line “Kinase 2027– poster abstract submission”. Authors submissions should be focused on kinase modulators, including inhibitors, activators and degraders. You can download an Abstract_Template. Selected poster presenters will have the opportunity to give a flash presentation; please indicate if you would like to be considered for a flash poster presentation.  First place poster prize winners will receive a complimentary year of full SCI membership.

---

Call for oral abstracts

If you would like to give an oral presentation, please send an abstract of maximum one A4 page or up to 300 words, indicating title and authors, to conferences@soci.org by Friday 29 January 2027 with the subject line “Kinase 2027– oral abstract submission”. You can download an Abstract_Template. Talks and reviews are being sought across a range of topics including, but not limited to:

• Medicinal chemistry case studies
• First disclosures of kinase modulators clinically approved or in clinical development
• Targeted kinase degradation
• Novel pharmacology and kinase targets
• Emerging technologies for targeting, assaying and modulating kinase targets

---

Bursaries

A limited number of student bursaries are available as a contribution to the cost of registration fees, travel and accommodation. For more information and to receive an application form, please contact conferences@soci.org with “Kinase 2027 – student bursary” in the title by Friday 12 March 2027 .

---

Confirmed Speakers

Prof Stefan Knapp, University of Frankfurt, Germany
Prof Angela Russell, Oxford University, UK
Enabling CNS disease research via kinase targeted induced proximity approaches
Dr William Farnaby, University of Dundee, UK
Discovery of Zilurgisertib, a potent and selective ALK2 inhibitor to treat a rare bone disease
Dr Thomas Ullrich, Novartis, Switzerland
Audrey-Rose Skinner, Activate Scientific, UK

---

Programme

The full programme will be confirmed in due course.

SCI’s Fine Chemicals Group and RSC’s Biological and Medicinal Chemistry Sector are committed to promoting diversity and equality in the chemical sciences. We aim to identify high quality speakers for all our conferences with inclusivity of gender and ethnicity. Attendees from all backgrounds and ages are welcome.

---

Sponsorship

For further information and prices, please email conferences@soci.org

---

Accessibility Grants

SCI accessibility grants are available to support SCI members with disabilities, long term health conditions, those who require a carer, and members who are nursing parents to attend SCI events. Download an application form to apply for a grant.

---

Venue and Contact

---

Fees

---

Booking Process/Deadlines

Booking terms and conditions

---

Travel

The AstraZeneca site is a 30-minute walk or a 5–10-minute bus journey. Buses run every 5-9 minutes from Cambridge station to the Addenbrookes site. For further details please see the link https://transport.cambridgeshirepeterborough-ca.gov.uk/buses/bus-timetables/ Although there is no parking available on site, delegates can drive and use the Cambridge park and ride sites: https://cambridgeparkandride.info/

Cambridge South railway station will be opening in June 2026. This will be a short distance from the conference venue.

---

CPD Info

All delegates attending this meeting are able to claim CPD points.

---

---

---

Organising committee

Al Dosseter, Medchemica
Ray Finlay, AstraZeneca
Nicole Hamblin, Rathlin Therapeutics
Suzanne O'Connor, University of Dundee
Asier Unciti-Broceta, University of Edinburgh

---